Characterization of the Plasma Proteome Following Left Ventricular Assist Device Implantation

University of Colorado, Denver20 enrolled

Overview

The purpose of this study is to characterize changes in the plasma proteome over time following left ventricular assist device (LVAD) implantation.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Ventricular Dysfunction, Left

Interventions

LVADDEVICE

Eligibility

Sex: ALLMin age: 21 YearsMax age: 90 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Planned HeartMate II LVAD implantation * Planned warfarin (goal INR, 2.0-3.0) and low-dose aspirin therapy post-LVAD placement Exclusion Criteria: * Prior history of mechanical circulatory support; * Body weight \< 110 lbs; * Pre-existing hemolytic, bleeding, or immunologic disorders prior to LVAD implantation; * Severe aortic stenosis; * Renal failure requiring dialysis; * Hepatic dysfunction resulting in severe coagulopathies; * Recent serious infection; * Current need for prolonged ventilatory support; * Prior organ transplantation; * Blood transfusion within 14 days of the first planned study blood draw; * Concomitant immunosuppressant or chemotherapeutic agents; * Pregnant women; * Decisionally challenged or prisoners; * Unwilling to provide written informed consent

Locations (1)

University of Colorado Anschutz Medical Campus

Aurora, Colorado, United States

Outcomes

Primary Outcomes

Quantitative differences in plasma protein abundance

Time frame: Days 7, 14, 30, 60, 90, and 180 post-LVAD implantation

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.